Conference Coverage
about 1 month ago
CORE-008: Cretostimogene achieves high CR rate in high-risk NMIBCabout 1 month ago
NDV-01 produces robust 9-month results in high-risk NMIBCLatest News
Jan 05, 2026 | News
Permanent J code for mitomycin for intravesical solution now in effect
Study validates Decipher as a predictor of early biochemical recurrence in prostate cancer
Jan 05, 2026
Beyond the clinic: Physician presence on social media
Jan 05, 2026
FDA updates in urology: December 2025
Jan 02, 2026
The UroOnc Minute: En bloc resection vs TURBT, with Jeremy Y.C. Teoh, MBBS, FRCSEd, FCSHK, FHKAM
Jan 02, 2026
Advertisement
Shorts
1:05
Aleece Fosnight, MSPAS, PA-C, on hormonally mediated bladder symptoms and IC/BPS
12 hours ago
by
Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, MSCP, HAES
1:05
Maxwell Sandberg, MD, outlines trial design for study evaluating treatment of RCC with a tumor thrombus
4 days ago
by
Maxwell L. Sandberg, MD
1:16
How an MMAI test can provide reassurance regarding prostate cancer treatment decisions
4 days ago
by
Daniel E. Spratt, MD
1:08
Jesse Mills, MD, on testosterone therapy and cardiovascular health
6 days ago
by
Jesse N. Mills, MD
1:03
Helen L. Bernie, DO, MPH, outlines how she evaluates hypogonadism
7 days ago
by
Helen L. Bernie, DO, MPH
1:04
Dean Elterman, MD, MSc, FRCSC, describes the efficiencies of the Zenflow system for BPH
8 days ago
by
Dean Elterman, MD, MSc
0:51
How the ProVee System for BPH preserves sexual function
11 days ago
by
Steven A. Kaplan, MD
0:57
Ilaha Isali, MD, MSc, on X chromosome biology and bladder cancer
12 days ago
by
Ilaha Isali, MD, MSc
1:13
Aleece Fosnight, MSPAS, PA-C, on why progesterone affects your bladder during your cycle
13 days ago
by
Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, MSCP, HAES
1:04
Dean Elterman, MD, MSc, FRCSC, on the advantages of the nitinol-based Zenflow system
14 days ago
by
Dean Elterman, MD, MSc
Dr. Laura Sena discusses ongoing trials of bipolar androgen therapy in prostate cancer
Bipolar androgen therapy is being explored in trials with enzalutamide (Xtandi), olaparib (Lynparza), and nivolumab (Opdivo), explains Laura Sena MD, PhD.
Podcasts
Videos
Urology Times Digital Edition
"The OBBA includes broad and sweeping changes that will have a profound impact," writes Allan Shen, CFP.
Jaeger emphasized that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication
The trial will assess the effect of adding docetaxel to SOC hormone therapy plus apalutamide in mCSPC.
The phase 1 trial is assessing VIR-5500 as both a monotherapy and in combination with ARPIs in prostate cancer.
"Suctioning technology for mini-PCNL is an improvement on relying on passive outflow," says Mantu Gupta, MD.
SBRT demonstrated favorable 4-year biochemical recurrence-free survival with a manageable safety profile.
"My pragmatic takeaway is that for patients who experience spasm or leak despite anticholinergics, this is a great thing to consider," says Mark D. Tyson II, MD, MPH.
The study is assessing the safety and tolerability of the CaverSTIM device for ED after surgical removal of the prostate.
Data showed that adding niraparib to AAP significantly improved radiographic progression-free survival in this patient population.
This announcement follows positive top-line data from a phase 1b/2a clinical trial of EG110A in patients with NDO following a spinal cord injury.
Continuing Medical Education
Advertisement
All News
Advertisement
As the year comes to a close, we revisit some of this year’s top content in female urology.
As the year comes to a close, we revisit some of this year’s top content in men's health.
As the year comes to a close, we revisit some of this year’s top content on bladder cancer.
As the year comes to a close, we revisit some of this year’s top content on prostate cancer.
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
As the year comes to a close, we revisit some of this year’s top content on benign prostatic hyperplasia.
As the year comes to a close, we revisit some of this year’s top content on genomic testing.
As the year comes to a close, we revisit some of the top Urology Times podcast episodes from 2025.
Joshua Palka, DO, reflects on the key trends that shaped urologic oncology in 2025, emphasizing the growing role of precision medicine across disease states.
As the year comes to a close, we revisit some of this year’s top content on urology coding and reimbursement.
Advertisement
Kenneth G. Nepple, MD, discusses a quality improvement initiative focused on identifying patients with prostate cancer who may be eligible for genetic testing.
As the year comes to a close, we revisit some of this year’s top content on prostate cancer.
In this episode, Timothy Daskivich, MD, joins host Adam Weiner, MD, to discuss survivorship and long-term quality-of-life considerations in prostate cancer care.
"The overall 0% impact to urology does not help urology practices deal with increasing costs incurred for staff, rent, supplies, and other overhead," write Jonathan Rubenstein, MD, and Mark Painter.
The application is supported by results from the phase 3 PIVOT-PO trial.
Advertisement
Advertisement
Trending on Urology Times
1
Beyond the clinic: Physician presence on social media
2
FDA updates in urology: December 2025
3
Daniel Spratt, MD, on using ArteraAI to guide salvage therapy decisions
4
Study validates Decipher as a predictor of early biochemical recurrence in prostate cancer
5